Mesenchymal Stem Cells and Blindness

In recent years, stem cell therapy has shown promise as a treatment for a number of diseases and conditions, including blindness. Mesenchymal stem cells (MSCs), a type of adult stem cell, have the ability to differentiate into a variety of cell types, including those of the eye. In animal studies, MSCs have been shown to improve vision in models of glaucoma and other eye diseases. MSCs can be derived from a variety of sources, including bone marrow, adipose tissue, and umbilical cord tissue. In most cases, MSCs are isolated from the patient's own tissue and then injected into the eye. This "autologous" approach eliminates the risk of rejection, as the cells are a perfect match for the patient. Clinical trials are ongoing to test the safety and efficacy of MSC therapy for blindness. Early results are encouraging, with patients reporting improvements in vision. In some cases, patients have even regained the ability to read and write. While the exact mechanism by which MSCs improve vision is not yet known, it is thought that the cells help to repair and regenerate damaged tissue in the eye. MSCs are also thought to possess anti-inflammatory properties.

 "Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative ...." 7 Mar. 2021, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001847/. Accessed 21 Oct. 2022.

 "Mesenchymal stem cell therapy in retinal and optic nerve diseases." 26 Nov. 2016, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120242/. Accessed 21 Oct. 2022.

 "Interaction Between Mesenchymal Stem Cells and Retinal ...." 17 Dec. 2020, https://www.frontiersin.org/articles/10.3389/fnins.2020.617377/full. Accessed 21 Oct. 2022.

The information below is the recommended stem cell therapy protocol for this condition 

Route of AdministrationDoseTime (Days)Total Cells
IV50,000,0003150,000,000
Intrathecal20,000,000120,000,000
Exosome Eye Drops10,000,0001N/A
Total170,000,000